Table 2.
The characteristics of insulin therapy in patients with T2DM.
| Variables | Total (n =39) | |
|---|---|---|
| No. | % | |
| Duration of insulin treatment (months) | 32.4 (36.6) | |
| Insulin treatment started >= 3 months before the visit | 28 | 75.70% |
| Basal insulin | 22 | 56.40% |
| Type of basal insulin* | ||
| Long-acting insulin analogue | 20 | 90.90% |
| Intermediate human insulin | 0 | |
| Biosimilar insulin | 2 | 9.10% |
| Basal insulin daily dose (IU) | 21.8 (10.8) | |
| Basal insulin daily dose (IU/kg) | 0.3 (0.1) | |
| Basal insulin number of injections | 1.1 (0.4) | |
| Prandial insulin | 5 | 12.80% |
| Type of prandial insulin* | ||
| Short-acting insulin analogue | 4 | 80.00% |
| Rapid-acting human insulin | 0 | |
| Biosimilar insulin | 1 | 20.00% |
| Prandial insulin daily dose (IU) | 19.0 (8.2) | |
| Prandial insulin daily dose (IU/kg) | 0.2 (0.0) | |
| Prandial insulin number of injections | 2.4 (0.9) | |
| Premix insulin | 18 | 46.20% |
| Type of Premix insulin* | ||
| Premixed analogue insulin | 3 | 16.70% |
| Premixed human insulin | 15 | 83.30% |
| % of basal / % of prandial | ||
| 25/75 | 0 | |
| 30/70 | 5 | 27.80% |
| 50/50 | 2 | 11.10% |
| 60/40 | 0 | |
| 65/35 | 0 | |
| 70/30 | 11 | 61.10% |
| 75/25 | 0 | |
| Premix insulin daily dose (IU) | 55.7 (18.2) | |
| Premix insulin daily dose (IU/kg) | 0.7 (0.3) | |
| Premix insulin number of injections | 1.9 (0.3) | |
| Devices used by the patient** | ||
| Reusable pen | 15 | 38.50% |
| Disposable pen | 16 | 41.00% |
| Vials | 11 | 28.20% |
| Pump | 0 | |
| Patient self-adjusts insulin dose | 18 | 46.20% |
Note: *A patient could receive more than one year of basal/prandial/premix insulin, **A patient could use more than one device.